Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.
What fueled the previous growth in the heterozygous familial hypercholesterolemia management market?
There has been a swift expansion in the market size for the management of heterozygous familial hypercholesterolemia in recent years. Its growth is anticipated to shoot up from $10.84 billion in 2024 to a staggering $12.07 billion in 2025, with a remarkable compound annual growth rate (CAGR) of 11.3%. The significant growth during the historic period can be attributed to factors such as the escalating incidence of cardiovascular diseases, government-led initiatives, heightened investment in research and development activities, increased awareness and diagnosis of Hefh, and the surging demand for personalized therapies.
What will be the heterozygous familial hypercholesterolemia management market size in the future?
In the upcoming years, the market size for the management of heterozygous familial hypercholesterolemia is projected to experience an accelerated expansion. It’s expected to grow to $18.37 billion by 2029, with a compound annual growth rate (CAGR) of 11.1%. The growth during the projected period can be ascribed to factors like the expanding telehealth services, the prevalence of chronic diseases, an increase in clinical trials, an aging population, and increasing number of drugs being tested. Major trends during the forecast period are expected to be the incorporation of digital health solutions, improvements in treatment choices, the progress in combination therapies, technological breakthroughs, and the development of novel therapies.
Get your heterozygous familial hypercholesterolemia management market report here!
What main drivers are fueling expansion in the heterozygous familial hypercholesterolemia management market?
The heterozygous familial hypercholesterolemia management market is projected to experience significant growth due to the escalating incidence of cardiovascular diseases. These diseases encompass conditions such as heart failure, stroke, and coronary artery disease, which impact the heart and blood vessels. The growing frequency of these diseases across the globe can be attributed to factors like unhealthy diets, inactive lifestyles, obesity, and an aged demographic. By effectively managing high cholesterol levels, the management of heterozygous familial hypercholesterolemia serves an essential function in preventing cardiovascular diseases, which can cause heart-related complications and atherosclerosis. According to data from the US government agency, the Centers for Disease Control and Prevention, in May 2024, around 805,000 heart attacks were reported in the United States in 2022. Of these, 605,000 were initial heart attacks, and 200,000 were experienced by individuals with a history of heart attacks. Therefore, this increased occurrence of cardiovascular diseases propels the growth of the heterozygous familial hypercholesterolemia management market.
What key areas define the segmentation of the global heterozygous familial hypercholesterolemia management market?
The heterozygous familial hypercholesterolemia management market covered in this report is segmented –
1) By Treatment Type: Statins, Ezetimibe, PCSK9 Inhibitors, Lomitapide, Mipomersen
2) By Route Of Administration: Oral, Injectable, Intravenous
3) By Patient Demographics: Children, Adults, Elderly
4) By Application: Hospitals, Medical Centers, Clinics, Other Applications
Subsegments:
1) By Statins: Atorvastatin, Simvastatin, Rosuvastatin, Pravastatin
2) By Ezetimibe: Ezetimibe (Monotherapy), Ezetimibe Combination Therapy (With Statins)
3) By PCSK9 Inhibitors: Alirocumab, Evolocumab
4) By Lomitapide: Lomitapide (Monotherapy), Lomitapide Combination Therapy
5) By Mipomersen: Mipomersen (Monotherapy), Mipomersen Combination Therapy
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21204&type=smp
Who are the dominant players expanding their reach in the heterozygous familial hypercholesterolemia management market?
Major companies operating in the heterozygous familial hypercholesterolemia management market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb, AstraZeneca plc, Novartis International AG, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Merck KGaA, Regeneron Pharmaceuticals Inc., Ipsen S.A., Chiesi Farmaceutici S.p.A., Ferring Pharmaceuticals Limited, Esperion Therapeutics Inc., Aegerion Pharmaceuticals Inc., Verve Therapeutics Inc.
What are the key trends shaping the future of the heterozygous familial hypercholesterolemia management market?
Firms that hold a significant market share in the management of heterozygous familial hypercholesterolemia are concentrating their efforts on the creation of innovative solutions such as angiopoietin to address issues related to lipid metabolism and the reduction of cholesterol levels. Angiopoietin is a group of proteins that are instrumental in the regulation of the formation of blood vessels (angiogenesis) and the preservation of blood vessel stability. For example, in March 2023, Regeneron Pharmaceuticals Inc., a biotech firm based in the US, was granted authorization by the U.S. Food and Drug Administration (FDA) for the use of Evkeeza (evinacumab-dgnb) in the treatment of homozygous familial hypercholesterolemia (HoFH) in children aged between 5 and 11. This pioneering monoclonal antibody functions by suppressing ANGPTL3, a protein that obstructs lipid metabolism, thus decreasing levels of low-density lipoprotein (LDL) cholesterol and triglycerides. This approval signifies a new therapeutic choice for pediatric patients with limited treatment options and a heightened risk of cardiovascular incidents.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21204
Which regions are emerging as leaders in the heterozygous familial hypercholesterolemia management market?
North America was the largest region in the heterozygous familial hypercholesterolemia management market in 2024. The regions covered in the heterozygous familial hypercholesterolemia management market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Similar Reports By The Business Research Company:
Pediatric Bladder Treatment Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/pediatric-bladder-treatment-global-market-report
Pediatric Imaging Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/pediatric-imaging-global-market-report
Biosimilar Monoclonal Antibodies Global Market Report 2025
https://thebusinessresearchcompany.com/report/biosimilar-monoclonal-antibodie-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
